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118Custom-made versus off-the-shelf multibranched
endografts for endovascular repair of
thoracoabdominal aortic aneurysms
Theodosios Bisdas, MD, Konstantinos P. Donas, MD, Michel J. Bosiers, MD, Giovanni Torsello, MD, and
Martin Austermann, MD, Muenster, Germany
Objective: This study compared early outcomes between the custom-made and the new off-the-shelf multibranched
endograft (mbEVAR, t-branch; Cook Medical, Bloomington, Ind) for the endovascular repair of thoracoabdominal
aortic aneurysms (TAAAs).
Methods: Between January 2010 and January 2013, 46 consecutive patients with TAAAs underwent endovascular aortic
repair with mbEVARs. A custom-made device was used in 24 patients (group A, 52%), with Crawford classiﬁcation type I,
2 (8%); type II, 4 (17%); type III, 9 (38%); and type IV/V, 9 (38%), and the a t-branch endograft was used in 22 patients
(group B, 47%), with type II, 9 (41%); type III, 12 (55%); and type IV/V, 1 (4%). The main outcome measure was
technical success, deﬁned as successful target revascularization without occlusion of the bridging endografts or type I or
III endoleak at the completion angiography. Secondary end points were mortality, unplanned reinterventions, branch
occlusion, paraplegia, and persistent (after discharge) paraparesis.
Results: Technical success was 100% in both groups. The 30-day mortality was 8% in group A (n[ 2) and 0% in group B
(P[ .51). Survival rates at 6 months were 71% in group A (mean follow-up, 136 11 months) and 94% in group B (mean
follow-up, 6 6 3 months; (P [ .04). There was only one procedure-related death caused by cerebral bleeding and
herniation in group A. The freedom-from-reintervention rate at 6 months was 100% in group A (mean follow-up, 12 6
11.5 months) and 90% in group B (mean follow-up, 6 6 3.9 months; P [ .07). No branch occlusions were observed in
group A, whereas a branch occlusion occurred in three patients in group B (in all cases the bridging endograft for the
renal artery). In two patients, the possible reason for branch occlusion was a thrombophilic disorder, whereas in one
patient, the reason remains unknown. Paraplegia was observed in one patient in each group (group A: 4%; group B: 5%;
P [ .51) and persistent paraparesis in two patients in group A (8%) and in one patient (5%) in group B (P [ .94).
Conclusions: The t-branch device, with the unique advantage of direct implantation without any delay for manufacturing,
showed 100% technical success and comparable clinical outcomes to the traditional custom-made mbEVARs. Further
long-term evaluation remains mandatory. (J Vasc Surg 2014;60:1186-95.)The ﬁrst clinical evaluation of the custom-made multi-
branched endograft used for endovascular aneurysm repair
(mbEVAR) showed very promising outcomes in elective
cases and may be the approach of choice in multimorbid
patients due to the minimally invasive character (no aortic
clamping, no visceral ischemia).1-3 However, the custom-
made design has two considerable limitations: Firstly, it
has no standard branch conﬁguration applicable to all types
of aortic anatomy, and secondly, the manufacturing time
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6symptomatic and ruptured thoracoabdominal aortic
aneurysms (TAAAs), which still have to be repaired
through conventional surgery or off-the-shelf techniques.5
This delay also poses the risk of aortic rupture in asymp-
tomatic patients waiting for the device.5,6
To overcome these limitations, a new off-the-shelf
mbEVAR (t-branch; Cook Medical, Bloomington, Ind)6
has been manufactured and is now available for use in
Europe. The main characteristics are the standard design
and the ﬁxed position of the branches, suitable for at least
in 50% of TAAAs treated with a custom-made mbEVAR.4,7
The ﬁrst clinical evaluation of technical success and periop-
erative outcomes conﬁrmed the safety and effectiveness of
the device.8
However, whether the new standard design with the
ﬁxed branches conﬁguration is as equally effective as the
traditional custom-made version remains questionable.
We conducted this study to compare the efﬁcacy of the
t-branch with the standard custom-made mbEVAR in the
framework of a single-center experience.
METHODS
Between January 2010 and January 2013, mbEVARs
with four branches were implanted in 46 consecutive
Table I. Patient demographics and characteristics in both groups
Parametersa Group A (n ¼ 24) Group B (n ¼ 22) P
Males 21 (88) 15 (68) .22
Age, years 71 6 6 70 6 8 .7
Comorbidities
Arterial hypertension 23 (96) 21 (95) .51
Diabetes mellitus 1 (4) 1 (5) .51
Coronary artery disease 20 (83) 18 (81) .8
Chronic obstructive pulmonary disease 8 (33) 6 (27) .9
GFR, mL/min/1.73 m2 81 6 25 73.2 6 30 .36
Body mass index, kg/m2 26 6 3 25 6 3 .41
Tobacco use 13 (54) 14 (64) .72
ASA score
3 5 (21) 6 (27) .87
4 19 (79) 16 (73) .87
Symptomatology at admission
Asymptomatic aneurysms 20 (83) 18 (82) .79
Symptomatic aneurysms 4 (17) 4 (18) .79
Aneurysm characteristics
Crawford classiﬁcation
Type I 2 (8) 0 .51
Type II 4 (17) 9 (41) .13
Type III 9 (38) 12 (54) .38
Type IV 9 (38) 1 (5) .02
Postdissection aneurysms 2 (8) 3 (14) .92
Maximal aneurysm diameter, mm
Above the celiac trunk 57 (28-81) 61 (29-110) .11
At the level of renovisceral segment 43 (26-61) 37 (25-75) .04
Infrarenal 46 (21-102) 38 (17-69) .21
ASA, American Society of Anesthesiologists; GFR, glomerular ﬁltration rate.
aContinuous data are shown as mean 6 standard deviation or median (interquartile range), and categoric data as number (%).
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patients received a custom-made (group A, 52%; overall
number of branches, 96) and 22 patients an off-the-shelf
mbEVAR (t-branch group B, 48%; overall number of
branches, 88). The t-branch device was ﬁrst used in
November 2012. For comparability reasons, we included
only patients who received custom-made devices with
four branches. Patient characteristics and comorbidities
are presented in Table I. All patients provided written
informed consent for either procedure and the Institutional
Review Board approved the study protocol. After
November 2012, custom-made devices were implanted
only in elective patients who were anatomically unsuitable
for the t-branch endograft.4,7 No ruptured aneurysms
have been treated with the t-branch up to now.
Anatomic inclusion criteria for t-branch. Fig 1
summarizes the characteristics of the new device, which
have been described extensively elsewhere.4,7 The following
anatomic inclusion criteria for the t-branch were used:
1. Proximal to aneurysm: Nonaneurysmal thoracic aorta
ﬁxation segment proximal to the aneurysm with an
angle of <90 relative to the long axis of the aneu-
rysm, length of at least 25 mm (50 mm of wall con-
tact preferred), and diameter measured outer wall to
outer wall no greater than 30 mm and no less than
24 mm. Alternatively, the device may be attached
to a pre-existing thoracic endovascular graft.2. Visceral vessel anatomy: (a) four indispensable
arteries, (b) aortic diameter of >25 mm at the region
of the branches, (c) target vessel accessible from ante-
grade approach, (d) celiac and superior mesenteric
artery 6 to 10 mm in diameter, (e) renal arteries 4
to 8 mm in diameter, (f) distance between the cuff
and the corresponding arterial oriﬁce <50 mm, and
(g) the line between the cuff and the arterial oriﬁce
as projected onto the vessel wall deviates no more
than 45 from the long axis of the aorta.
3. Access: (a) adequate iliac/femoral access compatible
with a 22F (8.5 mm outer diameter) delivery system,
and (b) brachial, axillary or subclavian access vessel
size compatible with the delivery proﬁle of a 10F
or 12F introducer sheath (3.3 or 4 mm outer
diameter).
Treatment algorithm. Since November 2012, our
ﬁrst-line treatment of TAAAs has been the use of the
t-branch device, if applicable.4,7 Custom-made mbEVARs
are used only in patients where the t-branch endograft is
unsuitable. In the speciﬁc case of postdissection TAAAs
with a narrow true lumen at the level of the renovisceral
segment, a combination of two branches (for the celiac and
superior mesenteric arteries) and two fenestrations for the
renal arteries is preferred.
Implantation technique. The implantation technique
has been described extensively in a previous report.8
Fig 1. The new off-the-shelf multi-branched endograft (t-branch; Cook Medical, Bloomington, Ind): the introduction
system consists of a 22F Flexor (Cook Medical) introducer sheath (7.3-mm inner diameter and 8.5-mm outer
diameter) and a Captor (Cook Medical) hemostatic valve. The company provides also a universal distal body at four
different sizes (proximal diameter (D) always 22 mm; lengths (L) of 81, 98, 115, and 132 mm; 20F introduction
system). SMA, Superior mesenteric artery.
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ating room under ﬂuoroscopic control (Axiom Artis FA;
Siemens Medical Solutions, Forchheim, Germany). All
patients underwent general anesthesia and a totally percu-
taneous approach using the Prostar XL-10F vascular
closure device (Abbott Vascular, Redwood City, Calif). In
elective patients with small iliac vessels, a 10-mm polyester
bypass between the common iliac and the common femoral
artery was ﬁrst performed 3 to 4 weeks before implantation
to avoid severe surgical bleeding due to the advanced
heparinization needed for the endovascular repair. In these
patients, the mbEVAR is implanted through a small cut-
down in the groin.
After surgical exposure of the left axillary artery, the
sutures of the Prostar-XL closure device were placed in
both common femoral arteries. Heparin dosage was set
at a conservative of 100 IU/kg body weight, aiming for
an activated clotting time of at least 250 seconds. Acti-
vated clotting time measurements were performed every
30 minutes.In case of stenotic iliac vessels, a 22F Check-Flo Intro-
ducer sheath (Cook Medical) was provisory advanced
through the iliac arteries to assess the ability of the
branched endograft to pass through the external and com-
mon iliac arteries. If this maneuver was successful, the pro-
cedure was continued with precannulation with a Shepherd
Hook catheter (Boston Scientiﬁc, Natick, Mass) of the
superior mesenteric artery from the contralateral groin.
In patients with type I or II TAAAs, the proximal
thoracic component was implanted ﬁrst over a stiff Lunder-
quist wire (Cook Medical). (Of note, in asymptomatic
patients, we prefer a staged procedure, with an interval of
6 to 8 weeks between implantation of the thoracic and
the mbEVAR.) The branched endograft was then
advanced and deployed by withdrawing the outer sheath
so that the branches were located 10 to 20 mm above
the oriﬁce of the respective target vessel, which was marked
by the preplaced catheter (superior mesenteric artery) or by
Syngo fusion imaging (Siemens, Munich, Germany; Fig 2)
for the renal arteries and the celiac trunk. The reducing ties
Fig 2. Use of fusion imaging to identify the oriﬁces (blue circles) of the target vessels during implantation of a
multibranched endograft: (A) Angiography before precannulation of the superior mesenteric artery; (B) cannulation of
the left renal artery through the marked oriﬁce; and (C) exact alignment between the implanted bridging endograft and
the marked oriﬁce of the target vessel.
Fig 3. Control angiography (right anterior oblique view, 43)
through the celiac branch (yellow arrow) and identiﬁcation of an
intercostal artery (red arrow) that may serve as a collateral pathway
to the anterior spinal artery.
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ﬁnished with the implantation of the distal component
(tube or bifurcated device). All sheaths were removed
and the common femoral arteries were closed. We deploy
completely all aortic endografts before the transaxillary
delivery of the bridging endografts to avoid long occlusion
of the limbs and the hypogastric arteries.
After the aortic endografts were in place and the
femoral arteries were closed, the target vessels, except the
celiac trunk, were cannulated one after the other through
the branches using a 90-cm 8F shuttle sheath (Cook Med-
ical) combined, however, with the more ﬂexible dilator of
the 110-cm 7F-shuttle sheath (Cook Medical). In our
experience, the more ﬂexible dilator facilitates the advance-
ment of the sheath even in challenging anatomies of the
target vessels (eg, cephalic orientation of the renal arteries).
The branches were connected with the target vessels
via a balloon-expandable covered stent (V12 iCast/
Advanta [Atrium Medical Corp, Hudson, NH], Maquet
[Wayne, NJ], or BeGraft [Bentley InnoMed, Hechingen,
Germany]). The bridging endograft was routinely lined
with a self-expanding bare-metal stent to provide a more
gradual and stable transition of the covered stent. After
revascularization of the superior mesenteric artery and
both renal arteries, an angiogram of the aneurysm sac
through the still open branch of the celiac artery was per-
formed to demonstrate relevant intercostal or lumbar
arteries that might send branches to the anterior spinal
artery. If the angiogram unmasked such arteries (Fig 3),
the branch of the celiac trunk remained open and was con-
nected to the target vessel in a third planned procedure 6 to
8 weeks later. At the end of the procedure, the half of the
total heparin dosage was antagonized by protamine.
Fig 4. A, A preoperative computed tomography (CT) angiography shows a type II thoracoabdominal aortic aneurysm
(TAAA) with previous thoracic endografting as a staged procedure. B, Intraoperative angiography before the
implantation of the multibranched endograft. C, Control angiography after completion of the procedure. D, A
postoperative CT angiography after 12 months of surveillance.
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standardized postoperative management and surveillance
protocol. They were monitored in an intensive care unit
for a minimum of 48 hours with invasive arterial
blood pressure monitoring (mean target, 80-90 mm
Hg). Cerebrospinal ﬂuid drainage was selectively used
by anesthesiologists only in patients with signs of spinal
cord ischemia.
Postoperative imaging included a control computed
tomography (CT) angiography (by glomerular ﬁltration
rate >60 mL/min/1.73 m2) and X-ray imaging of the
stent. Follow-up imaging consisted of CT angiographies
and X-ray images at 6 and 12 months and annually there-
after. In case of renal impairment, native CT scan and
duplex ultrasound imaging were performed to assess the
aneurysm progression and the patency of the target vessels,
respectively. Figs 4 and 5 show CT angiographies before
and after endovascular repair of a TAAA with a custom-
made and off-the-shelf mbEVAR, respectively.
Outcome measures and deﬁnitions. The main
outcome measure of this study was the technical success
of the procedure in either group, deﬁned as the successful
deployment of the mbEVAR, the bridging stent grafts, and
the relining stents, without evidence of occlusion or type I
or III endoleaks at the completion angiography.Secondary outcomes were mortality, unplanned
procedure-related reinterventions, branch occlusion, para-
plegia, and persistent (after discharge) paraparesis. The
following CT ﬁndings for the branch vessels were indications
for unplanned reinterventions according to our algorithm:
1. Celiac artery: asymptomatic >50% stenosis, symptom-
atic occlusion/stenosis or any stent/stent graft fracture;
2. Superior mesenteric artery: any stenosis or stent/
stent graft fracture;
3. Renal arteries: asymptomatic >50% stenosis, symp-
tomatic (ﬂank pain, glomerular ﬁltration rate >15%
from baseline) occlusion/stenosis or any stent/stent
graft fracture.
The classiﬁcation system for spinal cord ischemia pub-
lished by Greenberg et al2 was adopted for paraplegia
(0 points: no movement; 1 point: minimal motion or
ﬂicker; 2 points: motion but not against resistance or grav-
ity) and paraparesis (3 points: motion against resistance and
gravity but no ability to stand or walk normally, 4 points;
ability to stand and walk with assistance).2
Statistical analysis. No power analysis was feasible in
this retrospective study. MedCalc 9.4.2.0 software (Med-
Calc Software, Ostend, Belgium) was used for statistical
Fig 5. A, A preoperative computed tomography (CT) angiography shows a type II thoracoabdominal aortic aneurysm
(TAAA) with previous thoracic endografting as staged procedure. B, Intraoperative angiography before t-branch
implantation. C, Control angiography after completion of the procedure. D, A postoperative CT angiography after
12 months of surveillance.
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as means 6 standard deviation and non-normally distributed
data as median (interquartile range [IQR]); categoric data are
given as the counts (percentage). Distributions of continuous
data were tested by means of D’Agostino-Pearson test. Nor-
mallydistributeddatawere analyzedbya t-test for independent
variables, and non-normally distributed data were analyzed by
theMann-WhitneyU test. Categoric variables were compared
by means of the c2 test. Finally, time-to-event analysis calcu-
lated the 6-month survival and freedom-from-reintervention
rates. A P value of<.05 was considered statistically signiﬁcant.RESULTS
Main outcome measure. Technical success was 100%
in both groups. Two of four patients with Crawford type II
TAAA (8%) in group A and nine patients with type II
TAAAs (40%) in group B were treated by a staged proce-
dure. A proximal thoracic endograft was already present
in two patients in group A due to a previous endovascular
treatment of a thoracic aortic aneurysm. The branch for the
celiac artery was left open in one patient in group B due to
the angiographic evidence of relevant intercostal arteries
(Fig 3), and a bridging endograft was placed in a third
stage. Table II provides an overview of the intraoperative
details and implanted materials. After November 2012,
eight of 26 patients (31%) were considered unsuitable for
the t-branch device and received a custom-made endograft.The mean operating time was 299 6 70 minutes in
group A and 264 6 37 minutes in group B (P ¼ .04).
Hospital median length of stay was comparable between
group A (10 days; IQR, 9-19) and group B (12 days; IQR,
8-14 days; P¼ .64). Median length of stay in the intermedi-
ate care unit was 82 hours (IQR, 45-177 hours) in group
A and 70 hours (IQR, 43-120 hours) in group B (P ¼ .26).
Secondary outcomes. The 30-day mortality was 8% in
group A (n ¼ 2) and 0% in group B (P ¼ .51). Reasons of
early death in group A were pulmonary embolism (n ¼ 1)
and cerebral bleeding with herniation (n ¼ 1). An acute
postoperative thrombocytopenia developed in the latter
patient, which likely led to this complication. Mean follow-
up was 13 6 11 months in group A and 6 6 3 months in
group B. No patients were lost in follow-up.
The survival rates at 6 months were 71% in group A
and 94% in group B (P ¼ .04). Reasons of death during
surveillance were pulmonary embolism (n ¼ 2), sepsis-
related multiple organ failure (n ¼ 2), and myocardial
infraction (n ¼ 1) in group A, and cardiac failure after cor-
onary artery bypass grafting (n ¼ 1) in group B.
The reintervention rate was 16% (n ¼ 4) in group A
and 14% (n ¼ 4) in group B (P ¼ .90). Table III provides
an overview of indications, time, and type of reinterven-
tions in both study cohorts. The freedom-from-
reintervention rate at 6 months was 100% in group A
(mean follow-up, 12 6 11.5 months) and 90% in group
B (mean follow-up, 6 6 3.9 months; P ¼ .07).
Table II. Intraoperative implantation details
Parametersa
Group A
(n ¼ 24)
Group B
(n ¼ 22)
Iliofemoral bypass 3 (13) 2 (9)
Cutdown in the groin 3 (13) 2 (9)
Aortic coverage
above CT, mm
110 (48-327) 180 (110-341)b
Distal component
None 4 (17) 7 (32)
Tube endograft 8 (33) 8 (36)
Bifurcated endograft 12 (50) 7 (32)
Bridging CS and RSc
Celiac trunk
CS
iCast/Advanta
V12d
22 (92) 20 (91)
BeGrafte 0 1 (5)
RS
SMARTf 15 (63) 9 (41)
Zilverg 1 (4) 1 (5)
Completeh 5 (21) 10 (45)
Superior mesenteric
artery
CS
iCast/Advanta V12 22 (92) 21 (95)
Fluencyi 2 (8) 1 (5)
RS
SMART 15 (63) 11 (50)
Zilver 2 (8) 1 (5)
Complete 6 (25) 10 (45)
Left renal artery
CS
iCast/Advanta V12 21 (88) 19 (86)
Viabahnj 2 (8) 6 (27)
BeGraft 0 1 (5)
RS
SMART 9 (38) 5 (23)
Zilver 0 1 (5)
Complete 2 (8) 7 (37)
Protegék 7 (29) 6 (27)
Everﬂexk 1 (4) 3 (14)
Right renal artery
CS
iCast/Advanta V12 22 (92) 20 (91)
Viabahn 1 (4) 2 (9)
BeGraft 1 (4) 1 (5)
RS
SMART 12 (50) 7 (32)
Zilver 1 (4) 0
Complete 5 (21) 4 (18)
Protegé 1 (4) 5 (23)
Everﬂex 1 (4) 4 (18)
CS, Covered stent; CT, celiac trunk; RS, relining stent; SD, standard
deviation.
aContinuous data are shown as median (interquartile range) and categoric
data as number (%).
bP ¼ .002.
cPatients having occluded target vessels or receiving no RSs are not
documented.
dAtrium Medical Corp, Hudson, NH.
eBentley InnoMed, Hechingen, Germany.
fCordis, Cordis, Miami Lakes, Fla.
gCook Medical, Bloomington, Ind.
hMedtronic, Minneapolis, Minn.
iBard Peripheral Vascular, Inc. Tempe, Ariz.
jW. L. Gore & Associates, Flagstaff, Ariz.
kCovidien, Mansﬁeld, Mass.
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observed, in group B, we observed occlusion of four of 88
branches (5%, P¼ .10) in three patients. In the ﬁrst patient,
both renal arteries were occluded on postoperative day 24
because of a type II heparin-induced thrombocytopenia.
The patient underwent urgent successful percutaneous
thrombectomy (AngioJet; Possis Medical Inc, Minneapolis,
Minn) of both target vessels and temporary dialysis. In the
second patient, occlusion of the right renal artery was
observed 7 months after the operation with ﬂank pain, and
the patient underwent also successful percutaneous throm-
bectomy with the Rotarex thrombectomy system (Straub
Medical, Wangs, Switzerland; Fig 6). Of note, this patient
suffers also from polycythemia vera, a blood disorder. The
last patient had an asymptomatic occlusion of the right renal
artery, which was diagnosed at the follow-up CT angiog-
raphy. The renal scintigraphy revealed that the left kidney
had taken over the total renal function; thus, any further
intervention to reopen the branch was not necessary.
Lastly, one patient in group A (4%) and one in group B
(5%, P ¼ .51) developed paraplegia after 32 and 28 hours,
respectively. Both patients had been treated for a Crawford
type II TAAA. The ﬁrst patient died of a sepsis-related mul-
tiorgan failure on postoperative day 45, and the second
patient is doing well and has partially recovered (from
0 to 2 points). Persistent paraparesis developed two
patients in group A (3 and 4 points, respectively, 8%) and
in one patient (4 points, 5%) in group B (P ¼ .94). The
onset of the symptoms in all but one patient was
>24 hours. At present all patients are able to walk, whereas
one patient (3 points) still requires assistance.
DISCUSSION
This is the ﬁrst study, to our knowledge, that compares
the efﬁcacy of the ﬁrst off-the-shelf mbEVAR (t-branch)
with the traditional custom-made device. From technical
and clinical points of view, the outcomes between the de-
vices were comparable. The technical success was 100%
in both groups. The overall mortality at 6 months for the
total cohort was 16% (seven of 44 patients), and no
TAAA ruptures were observed in either group during the
surveillance period. Compared with the t-branch device,
the custom-made devices showed a better early perfor-
mance (statistically not signiﬁcant), with a 6-month
freedom-from-reintervention rate of 100% compared with
90%, respectively.
Analyzing in details the results of our study, several
issues should be itemized. Firstly, the excellent technical
success rates for both devices are associated with the very
careful planning before the procedure. In particular,
implantation of the off-the-shelf device according to the
reported anatomic inclusion criteria remains essential.7
Based on them, the t-branch is theoretically applicable in
>60% of patients with TAAAs.4,7 This was conﬁrmed
also in our study, where 69% of the patients were suitable
for the off-the-shelf endograft. Taking this ﬁnding under
consideration, the current study suggests that not only
Table III. Indications and type of unplanned secondary procedures
Time Indication Procedures
Group A Group A
POM 16 Type Ia endoleak due to aneurysmatic degeneration of the
proximal descending aorta
Proximal extension of the mbEVAR with TEVAR
POM 25 Type III endoleak due to migration of the covered stent in
the right renal artery
Distal extension with an additional covered stent
POM 28 Type Ia endoleak due to aneurysmatic degeneration of the
proximal descending aorta
Proximal extension of the mbEVAR with TEVAR
supported by chimney endografting for the left subclavian
artery
POM 33 Type III endoleak due to fracture of the covered stent in
the celiac artery
Endovascular repair with an additional covered stent
Group B Group B
POD 6 Short dissection of the SMA distal to the relining stent Endovascular repair with extension of the relining stent up to
a dissection-free segment of the SMA
POD 24 Occlusion of both renal arteries Percutaneous thrombectomy (AngioJet)a
POM 7 Occlusion of the right renal artery Percutaneous thrombectomy (Rotarex)b
mbEVAR, multi-branched endograft; POD, postoperative day; POM, postoperative month; SMA, superior mesenteric artery; TEVAR, thoracic endovascular
aortic repair.
aPossis Medical Inc, Minneapolis, Minn.
bStraub Medical, Wangs, Switzerland.
Fig 6. Percutaneous transbrachial thrombectomy was required for the occluded branch of the right renal artery
7 months after t-branch implantation. A, Intraoperative angiography demonstrates the occluded right renal artery
(black arrow). B, Angiographic control of the branch after thrombectomy with the Rotarex thrombectomy system
(Straub Medical, Wangs, Switzerland) and (C) implantation of a balloon-expandable stent graft (BeGraft; Bentley
InnoMed, Hechingen, Germany). D, Control angiography conﬁrms the successful recanalization of the occluded
branch and the perfusion of the right kidney.
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1194 Bisdas et al November 2014symptomatic or urgent cases can now be treated immedi-
ately, but also that elective cases are not compelled to
wait for the manufacturing of the custom-made endograft
or bear the risk of aneurysm rupture during waiting.
The comparable efﬁcacy, however, does not automati-
cally mean that the off-the-self endograft should replace the
custom-made devices. There are still a number of anatomic
obstacles that violate the suitability of the t-branch device
or require the performance of adjuvant procedures (eg,
carotid-subclavian bypass, additional proximal thoracic
endografting) that might lead to additional morbidity.4
Such procedures are actually unnecessary in case of
custom-made mbEVARs and that still remains the main
advantage of the latter. We have already identiﬁed and re-
ported the main obstacles that would make theoretically
the t-branch endograft unsuitable for implantation4: (1) a
distance between the celiac trunk and the most caudal renal
artery >56 mm (60% of unsuitable patients), (2) insufﬁ-
cient diameter (<25 mm) at the level of the visceral arteries
(33%, mostly postdissection aneurysms), (3) upward orien-
tation of at least one renal artery (20%), (4) inadequate
(>40 mm) proximal landing zone (13%), and (5) a
distance <67 mm between the most caudal renal artery
and aortic bifurcation (7%). The latter limitation was
observed mostly in patients who had previous open repair
of the abdominal aorta with a bifurcated graft.
On the other hand, the aforementioned anatomic chal-
lenges can be successfully solved by means of custom-made
devices. The branches in the custom-made endografts are
usually placed at the most optimal position above the target
vessels, facilitating their catheterization. Besides, in type III
thoracoabdominal aortic aneurysms with a proximal landing
zone >32 mm in diameter, the custom-made device can be
ordered with a proximal diameter of 38 mm.4 In contrast,
the t-branch device, having a ﬁxed diameter of 34 mm,
requires in that case a proximal extension by means of an
additional thoracic endografting. Moreover, the custom-
made endograft can be manufactured with two stents at
the proximal part in contrast to the ﬁxed three stents of the
t-branch. This leads to less coverage of the thoracic aorta.4
Finally, an additional advantage of the custom-made
devices is that the distal diameter of the endograft can
vary by request compared with the ﬁxed diameter of
18 mm in the t-branch.4 By this means, distal extension
through a bifurcated endograft is not always necessary dur-
ing custom-made endografting. Said differently, use of
custom-made devices leads to less coverage of the aorta,
facilitates the catheterization of the target vessels, and
sometimes requires fewer implanted materials.
Another important issue is the survival rate of our study
cohort. Considering that >70% of our patients in both
groups (Table I) were multimorbid and elderly patients
unsuitable for open repair, the 6-month mortality rates of
16% in the total cohort is still encouraging. However, we
should highlight that the mbEVAR in such fragile patients
seems not to alter the natural history of the aneurysm,
considering that a respectable number of patients die
#6 months due to non TAAA-related reasons. Certainly,future studies should assess the efﬁcacy of mbEVAR in
younger and ﬁt individuals.
We observed four early branch occlusions in the group
of the off-the-shelf endograft and all at the level of the renal
arteries. The thrombophilic disorder was the leading cause
in two patients, whereas no anatomic or systemic reason
was identiﬁed in the third patient. As a result, no clear eval-
uation of the aforementioned occlusions can be performed.
However, we now focused our investigation on this issue to
clarify whether the off-the-shelf concept or the absence of a
dedicated bridging endograft leads to such occlusions. We
used in both patients a percutaneous thrombectomy sys-
tem. We prefer the AngioJet system in small vessels
(<6 mm) and the Rotarex system in larger vessels
(>6 mm); however, which is used always depends on the
surgeon’s preference. Our experience shows the Rotarex
thrombectomy system bears a higher risk of vessel injury
in the uncovered part of the target vessel; thus, we do
not recommend its use for small vessels.
Compared with our results, Mastracci et al9 showed in
650 patients with both fenestrated and branched endog-
rafts a 94% 1-year freedom from reintervention. A direct
comparison to our four-branched endografts is not feasible
because of the mixed population. In their separate analysis
in patients with TAAAs, they observed 80% 1-year freedom
from branch instability rate.9 Instability occurred in two
branches in our study, both after 1 year (one with migra-
tion and one with stent-graft facture, Table III). No deaths
from branch stent complications were reported.
Finally, encouragingly low paraplegia rates were
observed and in all cases were associated to an extensive
coverage of type II TAAAs. Although most of the patients
in group A presented with Crawford type III and IV and in
group B from Crawford type II and III TAAAs, the rate of
spinal cord ischemia remained comparable between the
groups. In this context, the following issues regardingneuro-
logic complications deservemention. The onset of the spinal
cord ischemia was observed in all but one patient 24 hours
after the intervention (70%), and this conﬁrms the results
of Greenberg et al,2 who also reported delayed onset of the
symptoms in 71% of their patients. For this reason, we have
extended the intensive care unit stay for at least 48 hours
for optimal monitoring of the arterial blood pressure.
To date, there are no well-investigated adjuncts or
techniques to prevent paraplegia for endovascular TAAA
repair compared with the established measures for open
repair (spinal cord hypothermia, cerebrospinal ﬂuid
drainage, or motor evoked or somatosensory evoked
potential). Our current algorithm consists of a postopera-
tive strict monitoring of the mean arterial blood pressure
(target, 80-90 mm Hg) and use of cerebrospinal ﬂuid
drainage only when spinal cord ischemia develops. Reasons
for the latter are the association of cerebrospinal ﬂuid
drainage with several neurologic complications (epidural
hematoma, infection, and intracranial hypotension syn-
drome)8,10,11 and the late onset of the spinal cord ischemia
after endovascular repair.2,12 However, the efﬁcacy of our
strategy requires further investigation.
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results of Etz et al13 for the extensive open surgical repair
of TAAAs. Harrison et al14 ﬁrst reported on the feasibility
of the controlled perfusion of segmental vessels with perfu-
sion branches as a useful adjunct to prevent spinal cord
ischemia during mbEVAR. This strategy, however, may
lead to more than one planned reintervention and carries
the risk of aneurysm-related complications due to the
delayed aneurysm exclusion. On the basis of our algorithm,
the use of “perfusion branches” depends on the angio-
graphic ﬁndings of the selective angiography through
the celiac trunk. Of note, we did not prefer a superselective
spinal cord arteriography because this has been related to
several complications in the literature.15
This study is not without some limitations. The study
design is retrospective, and the follow-up period was short.
The reason for this early 6-month analysis was to assess
whether continuing implantation of the off-the-shelf device
was safe not only in symptomatic/ruptured patients but
also in elective patients. This ﬁrst analysis showed a trend
for more renal branch occlusions after t-branch implanta-
tion, and our future research is now focused on this issue.
The deﬁnition of technical success and secondary proce-
dures was based on the intention-to-treat protocol; that is, if
the celiac branch was left open to prevent paraplegia or a
two-stage procedurewas preferred, thiswas neither technical
failure nor a secondary procedure according to our study
design. Thus, we reported unplanned procedure-related
reinterventions. Owing to the restricted number of patients
in each group of the Crawford classiﬁcation (Table I), no
further subgroup analysis was performed.
Finally, possible bias associated to the learning curve
and experience of the surgeons is minimized because all
patients were treated by the same surgical team. However,
we were not able to compare the time needed to place all
bridging endografts between custom-made devices and
the t-branch device because such a prospective analysis
was outside of the topic of this study.
CONCLUSIONS
We report the ﬁrst technical and clinical comparison
between the new off-the-shelf mbEVAR (t-branch) and
the custom-made devices for complex endovascular repair
of TAAAs. The results showed excellent technical success
and comparable 6-month clinical outcomes between the
endografts. This study provides the ﬁrst evidence of safety
and effectiveness of the t-branch compared with the well-
established custom-made device. Further assessment of
the branch stability and the device’s performance remains
mandatory and needs to be addressed in the next years.
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